According to Intra-Cellular Therapies's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 14.4946. At the end of 2023 the company had a P/S ratio of 14.9.
Year | P/S ratio | Change |
---|---|---|
2023 | 14.9 | -25.87% |
2022 | 20.1 | -61.45% |
2021 | 52.2 | -54.05% |
2020 | 114 | -99.64% |
2019 | > 1000 | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | -100% |
2015 | > 1000 | 7862.53% |
2014 | 951 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Xencor XNCR | 8.03 | -44.57% | ๐บ๐ธ USA |
MediciNova MNOV | 71.1 | 390.64% | ๐บ๐ธ USA |
Curis CRIS | 6.39 | -55.90% | ๐บ๐ธ USA |